Kristen M. Hege, M.D., has served as a member of our Board of Directors since August 2016. Dr. Hege retired as Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb Company, or BMS, a global biopharmaceutical company, a position she held from November 2019, when BMS acquired Celgene Corporation, a pharmaceutical company, or Celgene, until March 2023. She joined Celgene in 2010 as Vice President, Translational Development. Dr. Hege also held an active faculty position at the University of California, San Francisco Medical Center from 1996 to 2023, most recently as Clinical Professor of Medicine, Hematology/Oncology, serving in that role as a volunteer since 2008. Dr. Hege has served on the board of directors of Adaptimmune Therapeutics plc, a biopharmaceutical company, or Adaptimmune, since November 2023. She also previously served on the board of directors of Graphite Bio, Inc., a biotechnology company, from April 2021 until its reverse merger with LENZ Therapeutics, Inc. in March 2024. Dr. Hege received a B.A. in biochemistry summa cum laude from Dartmouth College and an M.D. from University of California, San Francisco.